Shenyang Xingqi Pharmaceutical Co., Ltd.

Shenyang Xingqi Pharmaceutical Co., Ltd. is a National High-tech Enterprise specializing in the research, development, production, and sale of ophthalmic medications. The company was listed on the ChiNext of the Shenzhen Stock Exchange on December 8, 2016, and is dedicated to promoting health and improving vision through its innovative product offerings. Xingqi emphasizes its core values of perseverance, innovation, responsibility, and win-win benefits in its operations. The company provides a diverse range of high-quality ophthalmic medications, including treatments for myopia in children, dry eye, infections, inflammation, and glaucoma, among others. Xingqi operates several research and technology centers, including the National Center for Enterprise Technology and the Myopia Prevention and Control Engineering Research Center for Children and Adolescents. Its manufacturing facility adheres to stringent quality standards, including US FDA cGMP and EU GMP, and features multiple production lines for various ophthalmic formulations. Xingqi collaborates closely with research institutions and medical experts to enhance its product offerings and has established a comprehensive sales network across medical institutions in China.

Innovation is the driving force for Xingqi Pharmaceutical to grow from strength to strength. Xingqi operates the National Center for Enterprise Technology, National Postdoctoral Research Station, Liaoning Provincial Enterprise Technology Center, Professional Ophthalmological Technology Innovation Center of Liaoning Province, and Myopia Prevention and Control Engineering Research Center for Children and Adolescents of Liaoning Province. In the field of R&D for ophthalmic drugs, Xingqi has established professional ophthalmic pharmaceutical research and evaluation platforms for conventional preparations, in-situ gels, sustained-release preparations, compatibility of pharmaceutical packaging materials, pharmacodynamics, pharmacokinetics, toxicology, etc. In October 2020, CNAS accredited the Quality Inspection Center of Xingqi in acknowledgement of its expertise in undertaking experiments and tests in accordance with recognized standards. Quality by Design and constant pursuit of elaboration. The Qipan Mountain Factory of Xingqi was fully operated in 2014. It was designed in accordance with the standards of US FDA cGMP and EU GMP and was constructed through collaboration with the world-class design team, equipment suppliers and construction companies. It has multiple production lines that are up to China’s GMP standards, for the manufacture of extract, single dose eye drops, multi-dose eye drops and eye gel. Xingqi Pharmaceutical focuses on the R&D and production of ophthalmic medications, takes a market-oriented approach and close collaboration with Chinese and international research institutions, medical institutes and ophthalmology experts to accelerate the transformation of scientific research achievements. Through academic promotion, Xingqi has optimized marketing. With a refined marketing system, Xingqi has established partnerships with distributors at various levels, enabling its product sales network into medical institutions at provincial, municipal and county levels nationwide.